GEG-Tech, adVentures Studio’s Genetic Engineering Firm, has positioned an offer in CAR T-cell Therapy (Cancer Immunotherapy).
Since the market authorised CAR T-cells in 2017, research labs and scientists were in need of advanced tools to generate CAR T-Cells.
GEG Tech’s Lenti-One Vectors are one of the best ways to generate CAR T-Cells and for T-Cell engineering.
This further strengthens GEG-Tech’s capacity to innovate in this revolutionary field.
With this new tool, GEG-Tech wants to contribute to the success of CAR T-Cells as a new class of drugs enabling potential for Cancer Immunotherapy.
